242 related articles for article (PubMed ID: 11850256)
1. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.
Stone JA; Holland SD; Wickersham PJ; Sterrett A; Schwartz M; Bonfiglio C; Hesney M; Winchell GA; Deutsch PJ; Greenberg H; Hunt TL; Waldman SA
Antimicrob Agents Chemother; 2002 Mar; 46(3):739-45. PubMed ID: 11850256
[TBL] [Abstract][Full Text] [Related]
2. Caspofungin acetate: an antifungal agent.
Hoang A
Am J Health Syst Pharm; 2001 Jul; 58(13):1206-14; quiz 1215-7. PubMed ID: 11449878
[TBL] [Abstract][Full Text] [Related]
3. Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants.
Migoya EM; Mistry GC; Stone JA; Comisar W; Sun P; Norcross A; Bi S; Winchell GA; Ghosh K; Uemera N; Deutsch PJ; Wagner JA
J Clin Pharmacol; 2011 Feb; 51(2):202-11. PubMed ID: 20679501
[TBL] [Abstract][Full Text] [Related]
4. Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits.
Groll AH; Gullick BM; Petraitiene R; Petraitis V; Candelario M; Piscitelli SC; Walsh TJ
Antimicrob Agents Chemother; 2001 Feb; 45(2):596-600. PubMed ID: 11158761
[TBL] [Abstract][Full Text] [Related]
5. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.
Petraitiene R; Petraitis V; Groll AH; Sein T; Schaufele RL; Francesconi A; Bacher J; Avila NA; Walsh TJ
Antimicrob Agents Chemother; 2002 Jan; 46(1):12-23. PubMed ID: 11751105
[TBL] [Abstract][Full Text] [Related]
6. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872).
Hajdu R; Thompson R; Sundelof JG; Pelak BA; Bouffard FA; Dropinski JF; Kropp H
Antimicrob Agents Chemother; 1997 Nov; 41(11):2339-44. PubMed ID: 9371330
[TBL] [Abstract][Full Text] [Related]
7. Potential for interactions between caspofungin and nelfinavir or rifampin.
Stone JA; Migoya EM; Hickey L; Winchell GA; Deutsch PJ; Ghosh K; Freeman A; Bi S; Desai R; Dilzer SC; Lasseter KC; Kraft WK; Greenberg H; Waldman SA
Antimicrob Agents Chemother; 2004 Nov; 48(11):4306-14. PubMed ID: 15504857
[TBL] [Abstract][Full Text] [Related]
8. Caspofungin: an echinocandin antifungal agent.
Stone EA; Fung HB; Kirschenbaum HL
Clin Ther; 2002 Mar; 24(3):351-77; discussion 329. PubMed ID: 11952021
[TBL] [Abstract][Full Text] [Related]
9. Caspofungin: first approved agent in a new class of antifungals.
Johnson MD; Perfect JR
Expert Opin Pharmacother; 2003 May; 4(5):807-23. PubMed ID: 12740003
[TBL] [Abstract][Full Text] [Related]
10. Disposition of caspofungin, a novel antifungal agent, in mice, rats, rabbits, and monkeys.
Sandhu P; Xu X; Bondiskey PJ; Balani SK; Morris ML; Tang YS; Miller AR; Pearson PG
Antimicrob Agents Chemother; 2004 Apr; 48(4):1272-80. PubMed ID: 15047529
[TBL] [Abstract][Full Text] [Related]
11. Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma.
Stone JA; Xu X; Winchell GA; Deutsch PJ; Pearson PG; Migoya EM; Mistry GC; Xi L; Miller A; Sandhu P; Singh R; deLuna F; Dilzer SC; Lasseter KC
Antimicrob Agents Chemother; 2004 Mar; 48(3):815-23. PubMed ID: 14982770
[TBL] [Abstract][Full Text] [Related]
12. Caspofungin acetate for treatment of invasive fungal infections.
Pacetti SA; Gelone SP
Ann Pharmacother; 2003 Jan; 37(1):90-8. PubMed ID: 12503942
[TBL] [Abstract][Full Text] [Related]
13. Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis.
Keating G; Figgitt D
Drugs; 2003; 63(20):2235-63. PubMed ID: 14498760
[TBL] [Abstract][Full Text] [Related]
14. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis.
Villanueva A; Gotuzzo E; Arathoon EG; Noriega LM; Kartsonis NA; Lupinacci RJ; Smietana JM; DiNubile MJ; Sable CA
Am J Med; 2002 Sep; 113(4):294-9. PubMed ID: 12361815
[TBL] [Abstract][Full Text] [Related]
15. Caspofungin.
Keating GM; Jarvis B
Drugs; 2001; 61(8):1121-9; discussion 1130-1. PubMed ID: 11465873
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological update on new infusion drugs.
Wilder GL
J Infus Nurs; 2001; 24(5):319-25. PubMed ID: 11575047
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age.
Sáez-Llorens X; Macias M; Maiya P; Pineros J; Jafri HS; Chatterjee A; Ruiz G; Raghavan J; Bradshaw SK; Kartsonis NA; Sun P; Strohmaier KM; Fallon M; Bi S; Stone JA; Chow JW
Antimicrob Agents Chemother; 2009 Mar; 53(3):869-75. PubMed ID: 19075070
[TBL] [Abstract][Full Text] [Related]
18. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits.
Groll AH; Mickiene D; Petraitis V; Petraitiene R; Ibrahim KH; Piscitelli SC; Bekersky I; Walsh TJ
Antimicrob Agents Chemother; 2001 Dec; 45(12):3322-7. PubMed ID: 11709303
[TBL] [Abstract][Full Text] [Related]
19. Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and AmBisome in combination with caspofungin to rats infected with Aspergillus fumigatus.
Wasan KM; Sivak O; Rosland M; Risovic V; Bartlett K
J Pharm Sci; 2007 Jul; 96(7):1737-47. PubMed ID: 17080414
[TBL] [Abstract][Full Text] [Related]
20. Single- and multiple-dose administration of caspofungin in patients with hepatic insufficiency: implications for safety and dosing recommendations.
Mistry GC; Migoya E; Deutsch PJ; Winchell G; Hesney M; Li S; Bi S; Dilzer S; Lasseter KC; Stone JA
J Clin Pharmacol; 2007 Aug; 47(8):951-61. PubMed ID: 17660480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
